Panitumumab

About Panitumumab

Panitumumab is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans).

Colorectal Cancer

RAS wild-type metastatic colorectal cancer (mCRC)

• Single-agent therapy

  • Indicated for treatment of wild-type RAS mCRC following disease progression after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy
  • 6 mg/kg IV every 14 days until disease progression or unacceptable toxicity

• Combination therapy

  • Indicated in combination with FOLFOX as first-line therapy for wild-type RAS mCRC
  • 6 mg/kg IV every 14 days until disease progression or unacceptable toxicity

KRAS G12C-mutated mCRC

• Indicated in combination with sotorasib for treatment of KRAS G12C-mutated mCRC in adults who received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
• 6 mg/kg IV every 14 days until disease progression, unacceptable toxicity, or until sotorasib is withheld or discontinued
• Refer to sotorasib prescribing information for recommended sotorasib dosing information

• Limitations of use

  • Not indicated for treatment of RAS-mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC
  • Not indicated for treatment of mCRC if RAS mutation status unknown

Dosage Modifications

Combination therapy with sotorasib

• If therapy with sotorasib is temporarily withheld or permanently discontinued, temporarily withhold or permanently discontinue panitumumab
• Refer to the sotorasib prescribing information for dose modifications for adverse reactions associated with use of sotorasib.

Infusion reactions

• Mild-moderate (grade 1-2): Reduce infusion rate by 50%
• Severe (grade 3-4): Terminate infusion; permanently discontinue depending on severity and/or persistence

Dermatologic reactions

• First occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to
• Second occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to
• Third occurrence of grade 3 dermatologic reaction: Withhold 1 to 2 doses; if reaction improves to
• Fourth occurrence of grade 3 dermatologic reaction: Permanently discontinue
• Grade 3 or 4 dermatologic reaction that does not recover to